(Q43602907)

25 November 2017

title

Gaps in knowledge and prospects for research of adjuvanted vaccines (English)

1 reference

25 November 2017

7

1 reference

25 November 2017

8

Vincenzo Cerundolo

1 reference

25 November 2017

2

Steven G Reed

1 reference

25 November 2017

Robert Seder

1

1 reference

25 November 2017

Derek O'Hagan

3

1 reference

25 November 2017

Padma Malyala

4

1 reference

25 November 2017

Ugo D'Oro

5

1 reference

25 November 2017

Donatello Laera

6

1 reference

25 November 2017

Lawrence Steinman

9

1 reference

25 November 2017

Sylvie Bertholet

10

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 June 2015

1 reference

25 November 2017

1 reference

25 November 2017

volume

33 Suppl 2

1 reference

25 November 2017

page(s)

B40-3

1 reference

The global value of vaccination

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

Edward Jenner and the history of smallpox and vaccination

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

inferred from DOI database lookup

7 January 2021

based on heuristic

Vaccine discovery and translation of new vaccine technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

Adjuvants--a classification and review of their modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

Beyond empiricism: informing vaccine development through innate immunity research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

Microparticle-based technologies for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.057

10.1016/J.VACCINE.2015.03.057

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference